SNUBI Research ::   (184 talks satisfying Presenter = 김주연)
All  Seminar  BioEMR  xMutant  SysBiol  MAInfo  J.Club  TopicSem  BookReading    This week    Help

ADD NEW USER

팀:   발표자:    제목/키워드:    날짜:   

2019-09:
05 김주연   TopicSem

2019-08:
05 김주연 Utility of extended Stargazer for calling star alleles with WGS data  BioEMR
24 김주연   J.Club

2019-07:
01 김주연 A clinical trial testing the effects of CYP2D6-guided versus usual opioid prescribing on pain control  BioEMR
15 김주연 ADR related synthetic association study: data processing flow and statistics  SysBiol
22 김주연 Refining method of candidate SAG extraction   TopicSem

2019-06:
08 김주연 Network, transcriptomic and genomic features differentiate genes relevant for drug response     J.Club
17 김주연 Candidate SAG characteristic examination based on drug-gene interaction status  TopicSem

2019-05:
02 김주연 Synthetic association analysis of PGx variants extracted from GWAS  TopicSem
27 김주연 Linkage disequilibrium between PGx GWAS and candidate SAG variants  BioEMR
27 김주연 Candidate SAG interpretation based on inter-ethnic variability  SysBiol

2019-04:
01 김주연 Star allele determination overview and exploration of methods  TopicSem
08 김주연 A disease-drug database to support drug prescribing based on patient pharmacogenomics test results  SysBiol
13 김주연 Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing     J.Club
15 김주연 CYP2D6 star allele calling with Stargazer  BioEMR

2019-02:
02 김주연 Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients     J.Club
11 김주연 Progress in troubleshooting of LSPE study error  BioEMR
14 김주연 Synthetic association analysis with significant variants from PGx GWAS studies  TopicSem
14 김주연 Evaluation of synthetic association detection using gene deleteriousness scores in hearing loss case  SysBiol

2019-01:
10 김주연 Evaluation of gene deleteriousness scores in the confirmation synthetic association signals  TopicSem

2018-12:
06 김주연 Evaluation of candidate SAGs with focus on drug-gene interactions  TopicSem
13 김주연 ITPA gene variants protecting against anemia as a case of synthetic association  SysBiol
26 김주연 Variants contributing to adverse drug reactions through synthetic association  Seminar
31 김주연 Addressing issues of applying the Large-Scale Population-Level Evidence Generation study in K-CDM  BioEMR

2018-11:
01 김주연 Progress in validation of synthetic association between candidate SAG and PGx variants  TopicSem
17 김주연 Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes     J.Club
19 김주연 Application of the Large-Scale Population-Level Evidence Generation R package in K-CDM  BioEMR

2018-10:
08 김주연 Evaluation of the candidate genes in synthetic association to tacrolimus ADR biomarkers  TopicSem
15 김주연 Evaluating relation between isoniazid and liver injury using KCDM  BioEMR
15 김주연 Evaluating association between isoniazid and liver injury using KCDM  BioEMR
18 김주연 Characteristics of candidate SAGs with regard to ethnicity  SysBiol

2018-09:
29 김주연 Quantifying the impact of rare and ultra-rare coding variation across the phenotypic spectrum     J.Club

2018-08:
09 김주연 Using TCGA for validation of synthetic association   SysBiol
09 김주연 Progress in evaluating relation between isoniazid and liver injury  BioEMR
20 김주연 Trial of validating genes with variants in synthetic association to PGx biomarkers using TCGA  TopicSem

2018-07:
05 김주연 Evaluation of ADR signal detected using K-CDM and KAERS reports  BioEMR
05 김주연 Evaluation of ADR signal detected using K-CDM and KAERS reports  BioEMR
14 김주연 Impact of germline and somatic missense variations on drug binding sites     J.Club
23 김주연 Statistics and interpretation of genes with variants in synthetic association to PGx variants  TopicSem

2018-06:
21 김주연 Interpretation of genes with variants in synthetic association to ADR biomarkers  TopicSem
21 김주연 Signatures and examples of synthetic association  SysBiol
21 김주연 Signatures and examples of synthetic association  SysBiol

2018-05:
24 김주연 Use of K-CDM and KAERS report for proactive surveillance of ADRs  BioEMR
26 김주연 Patient-Centered Precision Health In A Learning Health Care System: Geisinger’s Genomic Medicine Experience     J.Club
28 김주연 Characteristics of genes synthetically associated to ADR biomarkers   TopicSem

2018-04:
12 김주연 Generating evidence for the comparative effectiveness of treatment pairs using the LargeScalePopEst R package  BioEMR
12 김주연 Generating evidence for the comparative effectiveness of treatment pairs using the LargeScalePopEst R package  BioEMR
12 김주연 Generating evidence for the comparative effectiveness of treatment pairs using the LargeScalePopEst R package  BioEMR
16 김주연 Extracting genes with variants in synthetic association to PGx variants  TopicSem
26 김주연 Evaluation of extracting genes with variants in synthetic association to ADR biomarkers  SysBiol

2018-03:
05 김주연 Interpretation of PGx variant candidate SAGs  TopicSem

2018-02:
14 김주연 Linking K-CDM to KAERS for active ADE signal detection  BioEMR
24 김주연 Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention     J.Club
28 김주연 Interpretation of genes in synthetic association to PGx variants: a case study  SysBiol

2018-01:
02 김주연 Gene set annotation of genes synthetically associated with PGx variants in GWAS  TopicSem
11 김주연 Pathway annotation of genes synthetically associated to GWAS PGx variants  SysBiol
29 김주연 Interpretation of the relation between SAGs of PGx variants and ADEs  TopicSem
31 김주연 Pathway enrichment analysis for FDA and GWAS PGx variants  SysBiol

2017-12:
14 김주연 Gene set annotation for genes synthetically associated with PGx variants  SysBiol
16 김주연 Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing     J.Club

2017-11:
16 김주연 Using standard queries to analyze ADR risks across multiple institutions  SysBiol
16 김주연 Using standard queries to analyze ADR risks across multiple institutions  SysBiol
27 김주연 Finding genes synthetically associated with PGx variants of GWAS  TopicSem

2017-10:
14 김주연 Multidisciplinary model to implement pharmacogenomics at the point of care     J.Club
16 김주연 Variant level analysis of genes in synthetic association to PGx variants: case for rs4646244 TA, AA  SysBiol
16 김주연 Variant level analysis of genes in synthetic association to PGx variants: case for rs4646244 TA, AA  SysBiol
25 김주연 Finding genes synthetically associated to PGx variants in GWAS  TopicSem

2017-09:
11 김주연 Extracting variants associated to drug response from the NHGRI GWAS Catalog  SysBiol
13 김주연 Analysis of synthetically associated genes to PGx variants  TopicSem

2017-08:
07 김주연 Extraction and analysis of genes synthetically associated with PGx alleles  TopicSem
07 김주연 Results of predominant and synthetically associated genes to PGx alleles  SysBiol

2017-07:
03 김주연 Updated statistics for determining ADR risk according to PGx variant status using synthetic association  SysBiol
05 김주연 Variant level analysis of genes synthetically associated with PGx alleles  TopicSem
22 김주연 Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cas     J.Club

2017-06:
05 김주연 ADR risk determination according to PGx variant status쟵sing synthetic association  TopicSem

2017-05:
27 김주연 Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration-experience from a pediatric tertiary care facility     J.Club
29 김주연 ADR risk according to 8 PGx variant statuses using synthetic association  SysBiol

2017-04:
24 김주연 Statistics of updated PGx variants for synthetic association analysis  SysBiol
26 김주연 ADR risk determination according to PGx variant status using synthetic association  TopicSem

2017-03:
11 김주연 Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial     J.Club
13 김주연 Visualization of variants grouped by genes in synthetic association with PGx variants  SysBiol
22 김주연 ADR risk determination according to PGx variant status using synthetic association  TopicSem

2017-02:
01 김주연 ADR risk determination according to FDA or PREDICT SNP genotype using synthetic association  TopicSem

2017-01:
23 김주연 Chromosomal distribution of variants synthetically associated with pharmacogenomic SNPs  SysBiol

2016-12:
10 김주연 Identification of causal genes for complex traits     J.Club
12 김주연 Determining adverse drug event risk according to FDA SNP genotype  SysBiol
12 김주연 Determining adverse drug event risk according to FDA SNP genotype  SysBiol
12 김주연 Determining adverse drug event risk according to FDA SNP genotype  SysBiol
12 김주연 Determining adverse drug event risk according to FDA SNP genotype using synthetic association  SysBiol
26 김주연 Determining ADR risk according to FDA & PREDICT SNP genotype  TopicSem
30 김주연 Determining ADR risk according to FDA & PREDICT SNP genotypes  Seminar

2016-11:
09 김주연 Gene score distribution of genes including or proximate to pharmacogenomic SNPs  TopicSem

2016-10:
10 김주연 South Korean geriatrics on Beers Criteria medications at risk of adverse drug events  TopicSem
31 김주연 Results of variant-centric approach for MRONJ  SysBiol
31 김주연 Human BioPathway Databases  SysBiol

2016-09:
19 김주연 Risk for ADEs in South Korean geriatrics from Beers Criteria medications  SysBiol
24 김주연 The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy     J.Club

2016-08:
01 김주연 Distribution of F10 mutations in the 1000 Genomes phase 3 population  SysBiol
10 김주연 Finding genomic features that affect drug response  TopicSem

2016-07:
09 김주연 Computational discovery of transcription factors associated with drug response     J.Club
11 김주연 Assessing drug response based on genetic mutation and expression  TopicSem

2016-06:
08 김주연 Mutations that change drug response due to altered gene expression  TopicSem
13 김주연 Detecting candidate variants of MRONJ occurrence  SysBiol

2016-05:
02 김주연 Predicting drugs related to treatment failure based on CNVs  TopicSem

2016-04:
25 김주연 CNV and gene expression profile in 1000 Genomes phase 3 population  SysBiol
25 김주연 CNV and gene expression profile in 1000 Genomes phase 3 population  SysBiol
25 김주연 Association between CNV and gene expression using 1000 Genomes data  SysBiol
25 김주연 Copy number variation and gene expression in 1000 Genomes phase 3 population  SysBiol
25 김주연 Association between CNV and gene expression using 1000 Genomes data  SysBiol

2016-03:
08 김주연 Review of very important pharmacogenes in PharmGKB  SysBiol
23 김주연 Predicting high risk drugs in 1KP based on pharmacogene CNVs  TopicSem

2016-02:
15 김주연 Variant centric analysis for MRONJ  TopicSem
20 김주연 A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program     J.Club

2016-01:
06 김주연 Finding genetic variants associated with increased risk for BRONJ  TopicSem
19 김주연 Model on predicting patients likely to benefit from preemptive genotying  SysBiol

2015-12:
02 김주연 Breakeven analysis of preemptive genotyping  TopicSem
12 김주연 Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians     J.Club
15 김주연 Review of clinical outcomes from pharmacogenotyping  SysBiol
29 김주연 Indications and pharmacologic action of frequently prescribed drugs in US and South Korea  SysBiol

2015-11:
03 김주연 Review of pharmacoeconomic analysis methods  SysBiol
24 김주연 Application of breakeven analysis for preemptive genotyping  SysBiol

2015-10:
13 김주연 Review of pharmacogene-related ADRs in Koreans  SysBiol
26 김주연 Economic evaluation of preemptive genotyping  TopicSem

2015-09:
01 김주연 Distribution of drug usage extent in HIRA 2011 patients  SysBiol
12 김주연 Electronic health record design and implementation for pharmacogenomics: a local perspective     J.Club
16 김주연 Preemptive genotyping to prevent ADEs: figures and tables  TopicSem
22 김주연 Overview of Korea Adverse Event Reporting System  SysBiol

2015-08:
05 김주연 Results for preemptive genotyping to prevent adverse drug events  TopicSem
11 김주연 Trend in predicted number of people with serious AE over year 2011  SysBiol

2015-07:
07 김주연 Refined figures for patient demographics and calculation results of preemptive PG study  SysBiol
11 김주연 Refined figures for patient demographics and calculation results of preemptive PG study  SysBiol
28 김주연 Progress of figures on number of patients predicted to have AEs based on genotype  SysBiol

2015-06:
13 김주연 Adoption of a clinical PGx implementation program during outpatient care--initial results of the University of Chicago “1,200 Patients Project”     J.Club
16 김주연 Additional results of preemptive genotyping calculation algorithm using 1KP ancestry  SysBiol
16 김주연 Additional results of preemptive genotyping calculation algorithm using 1KP ancestry  SysBiol
29 김주연 Preemptive genotyping to prevent ADEs: ancestry-weighted calculation results  TopicSem

2015-05:
06 김주연 Calculation workflow for showing need for preemptive genotyping   SysBiol
26 김주연 Calculation scheme for predicting number of people with adverse events using ancestry-weights  SysBiol
27 김주연 Preemptive genotyping for ADE prevention: ancestry weighted calculation scheme  TopicSem

2015-04:
11 김주연 Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands      J.Club
27 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2015-03:
23 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2015-02:
02 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem
07 김주연 PG4KDS: A Model for the Clinical Implementation of Pre-Emptive Pharmacogenetics     J.Club
17 김주연 Statistics of processed year 2011 HIRA data  SysBiol

2015-01:
05 김주연 AMIA: Developing a Formal Representation for Medication Appropriateness Criteria   TopicSem
06 김주연 Comparison of statistics for inpatient and outpatient prescriptions of year 2011  SysBiol
26 김주연 SG05 rarepedia     Seminar
27 김주연 Overview of HIRA 2011 statistics  SysBiol

2014-12:
13 김주연 Development and use of active clinical decision support for preemptive pharmacogenomics     J.Club
16 김주연 Statistics of year 2011 HIRA data and PREDICT study data  SysBiol
16 김주연 Statistics of year 2011 HIRA data and PREDICT study data  SysBiol
29 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2014-11:
24 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem
24 김주연 SG05 Interpretation  Seminar
25 김주연 Calculating number of preventable adverse events with HIRA data using PREDICT algorithm  SysBiol

2014-10:
20 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem
22 김주연 Statistics of year 2011 HIRA patient and drug data  SysBiol

2014-09:
01 김주연 IODINE: prescriber & patient-accessible health information platform  TopicSem
20 김주연 Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems     J.Club
24 김주연 Calculation of number of potential adverse events prevented from preemptive genotyping-meta analysis process  SysBiol
24 김주연 Calculation of number of potential adverse events prevented from preemptive genotyping-meta analysis process  SysBiol

2014-08:
16 김주연 Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol     J.Club
19 김주연 Examination of number of preventable adverse events using PREDICT algorithm and HIRA drug claims data  SysBiol
26 김주연 Review of Iodine website  SysBiol
31 김주연 Review of the roles and mechanisms of proteins encoded by pharmacogenes  SysBiol

2014-07:
01 김주연 Examination of number of patients prescribed drugs with clinically severe AEs modulated by variant alleles  SysBiol
22 김주연 Examination of the frequency of pharmacogenetic medication prescribing in Korea  SysBiol
22 김주연 Examination of the frequency of pharmacogenetic medication prescribing in Korea  SysBiol
26 김주연 Computational Drug Repositioning: From Data to Therapeutics     J.Club
28 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2014-06:
10 김주연 Review of FDA-approved drugs with pharmacogenomic information in their labeling  SysBiol
30 김주연 Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2014-05:
17 김주연 Optimizing Drug Outcomes through Pharmacogenetics: a Case for Preemptive genotyping     J.Club
20 김주연 Examination of data in Korea Health Insurance Review & Assessment Service  SysBiol
28 김주연 Identifying the need of prospective genotyping  TopicSem

2014-04:
08 김주연 Review of Cancer Genome Project database  SysBiol
08 김주연 Review of Cancer Genome Project database   SysBiol
08 김주연 Review of Cancer Genome Project database   SysBiol
08 김주연 Review of Cancer Genome Project database   SysBiol
28 김주연 Finding genomic factors that regulate drug efficacy  TopicSem

2014-03:
18 김주연 Role and mechanisms of drug targets, enzymes, transporters, and carriers  SysBiol
18 김주연 Role and mechanisms of drug targets, enzymes, transporters, and carriers  SysBiol
29 김주연 DGIdb: mining the druggable genome     J.Club

powered by SNUBI